(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.49%.
Vaxcyte's earnings in 2026 is -$657,201,000.On average, 12 Wall Street analysts forecast PCVX's earnings for 2026 to be -$818,203,416, with the lowest PCVX earnings forecast at -$1,078,903,238, and the highest PCVX earnings forecast at -$571,798,557. On average, 10 Wall Street analysts forecast PCVX's earnings for 2027 to be -$882,216,578, with the lowest PCVX earnings forecast at -$957,029,508, and the highest PCVX earnings forecast at -$787,597,531.
In 2028, PCVX is forecast to generate -$855,550,972 in earnings, with the lowest earnings forecast at -$1,208,474,258 and the highest earnings forecast at -$655,644,018.